Barclays’s Regenxbio RGNX Stock Holding History

Barclays’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,800	Closed	-$225K	–	5579
2026 Q1	$225K	Hold	26,800	–	–	﹤0.01%	3617
2025 Q4	$386K	Buy	26,800 +5,400	+25%	+$67.3K	﹤0.01%	3995
2025 Q3	$207K	Hold	21,400	–	–	﹤0.01%	4274
2025 Q2	$176K	Hold	21,400	–	–	﹤0.01%	4360
2025 Q1	$153K	Buy	+21,400	New	+$159K	﹤0.01%	4192
2024 Q2	–	Sell	-25,000	Closed	-$527K	–	5229
2024 Q1	$527K	Buy	+25,000	New	+$445K	﹤0.01%	3555

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Barclays's RGNX Position: Q2 2026 in Review

Barclays reduced its Regenxbio (RGNX) stake by 35% in Q2 2026, selling an estimated $194K and leaving 44,067 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Barclays first reported a position in RGNX in Q4 2015 and has held it in 41 quarters since. The position peaked at $7.65M in Q4 2019. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Barclays held 44,067 shares of Regenxbio worth $528K as of Q2 2026.
Barclays sold 23,360 Regenxbio shares in Q2 2026, an estimated $194K.
Regenxbio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3189 holding.
Barclays first reported a position in Regenxbio in Q4 2015 and has held it in 41 quarters since.
Barclays's Regenxbio position peaked at $7.65M in Q4 2019.
164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.